Introduction
Currently available cytotoxic anti-cancer drugs inhibit cellular proliferation by various molecular mechanisms such as inhibition of DNA topoisomerases or folate-dependent enzymes or by interference with microtubular dynamics, to name only a few (for review see Ferrante et al., 1999) . Disturbing central functions of proliferating cells, drug treatment leads to cell cycle arrest and eventually cell death. Although a number of key regulatory events controlling apoptosis and the cell cycle are now understood along general lines, many open questions remain regarding the connectivity of known mechanisms with other cellular pathways. Understanding the molecular causes of toxic side effects or of pathways suppressing drug action will however be of great importance for the development of improved anticancer drugs. Identifying the complete set of genes that contribute to the induction of apoptosis would also be of immense value for our understanding of a variety of diseases that are characterized by impaired control of cell death (Nicholson, 2000) .
With the advent of genome-scale experimental setups it is now becoming possible to look at cellular pathways from a perspective that allows the discovery of many new, and often surprising, players and interconnections between pathways (Amundson et al., 1999; Brachat et al., 2000) . One of the major challenges accompanying large-scale experiments such as gene expression profiling with DNA microarrays (Schena et al., 1995 (Schena et al., , 1996 is to distinguish between central players with a direct, causative influence on the phenotypic outcome of a stimulus and unrelated side effects.
In this study we tested the hypothesis that some of the regulatory events that are central to the control of proliferation and apoptosis may be shared between different cancer drug treatment responses. We devized an experimental strategy for the identification and subsequent phenotypic testing of genes that are differentially regulated in several apoptotic pathways. Most steps of this procedure are suitable for upscaling to a high-throughput mode and should also be transferable to the analysis of other cellular pathways. Here, we show that a high percentage of candidate genes tested (four out of nine) indeed influenced proliferation or apoptosis of murine proB-cells when ectopically overexpressed, consistent with an involvement in apoptosis or cell cycle control.
Results

Gene expression analysis by cDNA microarrays
In a previous set of experiments we have compared transcriptional events in drug-induced apoptosis with those in a physiological pathway of cell death triggered by interleukin-3 (IL-3) deprivation. We found that responses to growth factor removal and inhibition of protein kinase C with staurosporine shared a significant number of regulatory events (Brachat et al., 2000) . In the present study we extended the investigation of drug treatment responses by analysing expression patterns of FL5.12 pro-B cells upon addition of cisplatin, camptothecin, methotrexate or paclitaxel respectively. Cisplatin acts mainly by binding to DNA and thereby inhibiting DNA synthesis (Cohen and Lippard, 2001) while camptothecin belongs to the group of topoisomerase I inhibitors, that cause proteinlinked DNA strand breaks and ultimately cell death (Schneider et al., 1990) . Methotrexate strongly binds to, and thereby inhibits dihydrofolate reductase, leading to a block in nucleotide synthesis (Olsen, 1991) . Paclitaxel, finally was chosen as a representative of drugs interfering with microtubule dynamics (Blagosklonny and Fojo, 1999) .
Poly-A + RNA was isolated from drug treated cells and from control cells after 0, 1, 6 and 20 h of incubation. Labeling of cDNAs, microarray hybridization and fluorescence detection was performed under standardized conditions by Incyte Corporation as for our previous analysis of IL-3 deprivation and staurosporine treatment responses. 8734 cDNA elements corresponding to 2588 unique annotated genes and 5393 ESTs from unique unnamed gene clusters were represented on the microarrays (Mouse GEM1).
Figure 1 summarizes transcriptional profiles of genes that were regulated by more than twofold in at least one of the response pathways. Although the kinetics of cell death induction was similar for different drug treatments (10 -30% dead cells after 20 h of treatment), the number of regulated genes differed significantly between experiments, with paclitaxel causing the weakest response (12 genes regulated by more than twofold). Most genes that were regulated upon multiple treatments also shared the direction of regulation. Genes that were differentially expressed upon methotrexate and also camptothecin addition for example were most likely either induced in both responses or repressed in both responses, providing additional evidence for shared transcriptional networks. The largest overlap was found between camptothecin and methotrexate with 42 shared genes as shown in Table 1 . Eleven genes responded to three of the four stimuli and one gene (TEAP) was even identified in all response-pathways. A striking feature of the group of commonly induced genes was an enrichment of p53-responsive, pro-apoptotic and antiproliferative genes like Ei24 (Lehar et al., 1996; Gu et al., 2000) , BTG2 (Rouault et al., 1996) , and cyclin G (Okamoto and Prives, 1999) . Only paclitaxel did not cause an induction of known p53 target genes. An inhibitory function had also been described previously for the glycoprotein GP49B (Wang et al., 2000) that we identified as induced in the camptothecin, cisplatin and paclitaxel responses. Induction of a murine homologue of the inhibitory protein tob (Matsuda et al., 1996) was observed in the camptothecin, cisplatin and methotrexate responses, further confirming the hypothesis that pathway intersections of upregulated transcripts should be enriched for anti-proliferative genes. The tetraspanin CD53 was upregulated upon camptothecin, cisplatin and paclitaxel treatment. It had been shown to be strongly induced in apoptotic neutrophils (Beinert et al., 2000) while work by Voehringer et al. (2000) points to a role for CD53 in protection against oxidative stress by raising levels of intracellular glutathione. Upregulation of CD53 may thus be a frequent, concomitant phenomenon of cells undergoing apoptosis but still processing conflicting, pro-and antiapoptotic signals.
The group of commonly repressed transcripts featured a number of metabolic genes such as the glucose isomerase 1, esterase 1, and glyceraldehyde-3- Figure 1 Combined expression profiles of four cancer drug treatment responses. Genes that were differentially regulated by more than twofold in at least one pathway are represented. The upper panel depicts upregulated and the lower panel downregulated genes with each line corresponding to one gene. Both panels indicate that the direction of regulation for any given gene usually is the same for different pathways Table 2 shows treatment-specific genes that were differentially regulated by more than 2.2-fold. The cellular reaction to camptothecin involved the largest number of specific transcriptional events, including 35 genes. In contrast, only the twist gene homolog was specific for paclitaxel treated cells. Interestingly, two pro-apoptotic regulators, BAD and BAK, were Our results demonstrate that prediction of the direction of gene regulation, based on knowledge about protein function, is often not possible. Genes that act pro-apoptotically in some cell-death pathways may for example not be involved as apoptosis regulators in the pathway under scrutiny. Alternatively, repression of pro-apoptotic genes during apoptosis induction may indicate the simultaneous activity of conflicting pathways that serve to 'compute' the net result of contradictory tendencies like stress-response and apoptosis. Negative feedback loops of gene expression may yet be another cause of counterintuitive regulation. One of the major strengths of microarray experiments is the possibility of generating global views on gene expression, unbiased by prior, incomplete, mechanistic knowledge. 
Selection of candidate genes
As all the drugs we have tested ultimately cause growth arrest and finally cell death we reasoned that the underlying transcriptional regulations were also likely to overlap and that the respective intersections may be enriched for important regulatory genes. From a pragmatic point of view, this proceeding also reduced the number of candidate genes to a set for which followup phenotypic analysis can be accomplished in parallel. We selected nine candidate genes for testing their influence on proliferation and cell death kinetics. Candidates were chosen if they were not previously known to have a role in pro-B cell apoptosis and if they were differentially expressed as a consequence of at least three apoptotic stimuli, including IL-3 deprivation and staurosporine treatment (Brachat et al., 2000) .
TEAP was induced between approximately two-and 10-fold in all six pathways. Carrier et al. (1999) originally identified TEAP as an acidic protein, expressed in thymus, that might be involved in thymocyte maturation but its precise function remained uncharacterized. GP49B was found to be upregulated upon staurosporine, cisplatin, methotrexate and paclitaxel treatment but was repressed during growth factor deprivation. GP49B encodes for an immunoreceptor tyrosine-based inhibitory motif-bearing receptor, that had been identified on mast cells, NK cells and on macrophages (Katz et al., 1996; Matsumoto et al., 2001 ). gp49B appears to act as an endogenous negative regulator of macrophage activation but its role in Bcells is yet to be elucidated. Another novel player, adenylate kinase 4 (AK4), was consistently downregulated in 4 (staurosporine, IL-3; camptothecin, methotrexate) pathways. The cellular role of AK4 is unknown but its localization to mitochondria would be consistent with roles in both, apoptosis or the proliferation-dependent control of energy metabolism (Yoneda et al., 1998; Noma et al., 2001) . Repression in three pathways (IL-3, camptothecin, methotrexate) was found for two immunophilins with peptidylprolyl cistrans isomerase (PPIase) activity, mFKBP25 and cyclophilin A. These proteins influence a large variety of cellular functions by regulating the activities of the respective binding partners. Among others, cyclophilin A and FKBP25 have been suggested to regulate the activity of histone deacetylases and transcription factors (Yang et al., 2001; Arevalo-Rodriguez et al., 2000) , but also of peroxiredoxins (Lee et al., 2001) . For onzin (Accession number: AF263458) we found strong (ninefold) repression upon camptothecin treatment but induction in the staurosporine and IL-3 deprivation responses. Onzin was discovered as a gene that is regulated by the leukemia inhibitory factor (LIF) in the mouse uterus but no function has been assigned to it yet. All remaining candidates, hemoglobin (IL-3, camptothecin, cisplatin), Ei24 (camptothecin, cisplatin, methotrexate), and Lipin1 (camptothecin, cisplatin, methotrexate) were induced in three pathways. The identification of hemoglobin as a strongly activated gene appeared surprising given its well-established role in oxygen transport in erythrocytes. As hemoglobin was even the most strongly induced gene of the IL-3 deprivation response we decided to include it into the list of candidate genes to be tested for their influence on cell survival and growth. Similarly to hemoglobin, the Lipin1 gene that is required for normal adipose tissue development (Peterfy et al., 2001) does not have a well established role in apoptosis or proliferative signaling and was also chosen for further analysis. In contrast to the other candidate genes, Ei24 is a known transcriptional target of the tumor suppressor p53 and has been previously described as being involved in growth control and apoptosis (Gu et al., 2000) . We included it in our analyses to test its role in pro-B cell apoptosis.
Phenotypic testing of candidate genes
Figure 2 depicts our strategy for analysing candidate genes after selecting them from the intersections of transcriptional responses. We combined the isolation of candidate gene cDNAs by reverse-transcription PCR with a highly efficient, recombination-based cloning system (Gateway TM , Life Technologies) to quickly generate expression constructs. The resulting plasmids were based on ecotropic retroviruses to allow for the fast generation of stable cell lines and to obtain high transduction efficiencies (approximately 70%) even in B-cells that are generally difficult to transfect. Candidate gene cDNAs were encoded on the same message as GFP and thus GFP fluorescence could be used to estimate relative expression levels by FACS analysis. A FACS-Calibur TM sorting device (Becton Dickinson) was also utilized for successive rounds of isolation of highly expressing cells. These populations were finally tested for their growth behavior and their changed kinetics of apoptosis induction upon IL-3 deprivation.
The CMV promoter was utilized to achieve high expression levels of candidate genes and GFP. We found that GFP signals were characteristically distributed within a population of transduced FL5.12 cells, depending on the candidate gene. Two independent retroviral transductions produced consistent results for the same expression construct with highly similar GFP + cell populations. Two thousand to 10 000 of the most strongly fluorescent cells were isolated by FACS sorting and re-grown in fresh medium. This procedure was repeated to obtain a population of maximally expressing cells. We consistently observed a strong correlation between the maximal obtainable expression level and growth behavior for all constructs. Expression of those candidate genes for which we were able to generate strongly expressing populations did not inhibit growth. In contrast, the transduction with other candidate genes that could not be strongly overexpressed, resulted in slow growing populations, suggesting an inhibitory or toxic effect of the respective genes. The relatively low average expression level within the growing population was presumably a Novel regulators of cancer drug response A Brachat et al consequence of a strong counter-selection against highly expressing cells. Our results concerning the inverse relation between expression levels and growth rates are summarized in Table 3 . Growth inhibitory phenotypes were found for TEAP, lipin1 and GP49B, providing the first evidence for a role of these genes in B-cell proliferation. Ectopic expression of the two cyclophilins, FKBP25 and cyclophilin A appeared to have no detrimental effect on cells, as we measured high levels of co-expressed GFP for these constructs and did not observe any growth defect.
In a second step we tested the influence of candidate gene expression on the kinetics of cell death induction upon IL-3 removal. Expression of most genes appeared to have only marginal if any effects on cell viability. This was true for both, wildtype and Bcl-2 overexpressing backgrounds. Surprisingly however, hemoglobin was identified as a novel pro-apoptotic factor. We had previously found hemoglobin as most strongly induced transcript of the IL-3 deprivation response, playing a yet undefined role during the loss of survival signaling by IL-3. In the present study, we compared the effects of ectopic expression of hemoglobin, anti-apoptotic Bcl-X L and pro-apoptotic Bax on FL5.12 viability. Only 10 -20% of hemoglobin overexpressing cells were still viable after 22 h of IL-3 deprivation as compared to 40 -50% of vector control cells (see Figure 3a) . Expression of hemoglobin thus had a similar effect on viability as high levels of the strong apoptotic inducer Bax. Accelerated cell death was accompanied by increased rates of DNA degradation as indicated by PI staining of cells with sub-2n DNA content (Figure 3b) . To characterize the influence of central regulators of cell death on the pro-apoptotic action of hemoglobin, we expressed hemoglobin in both, Bcl-2 and Bax overexpressing backgrounds and determined the percentage of apoptotic cells after 16 h of IL-3 deprivation. Bcl-2 very efficiently suppressed cell death induced by hemoglobin, while apoptosis was enhanced by hemoglobin in the Bax expressing background (Figure 3c ). To test the involvement of caspases in the pro-apoptotic effects of hemoglobin, we assayed cleavage of a fluorogenic caspase substrate either in the presence or in the absence of the caspase inhibitor Ac-DEVD-CHO. Hemoglobin expression led to a significant increase of caspase activity 16 h after removal of IL-3 as compared to the -DNA and vector control. The levels of caspase activity reached approximately 60% of those caused by Bax overexpression. Addition of caspase inhibitor completely abolished the generation of fluorogenic cleavage product, thus confirming that indeed caspases were responsible for cleavage ( Figure  3d ). Taken together, these results showed that hemoglobin has a previously unknown pro-apoptotic role in IL-3 dependent pro-B cells. Figure 2 Experimental flow-chart for the identification of regulators of apoptosis and proliferation, common to several cell death pathways. Murine FL5.12 pro-B cells were subjected to apoptosisinducing cancer drugs and transcriptional responses were monitored with cDNA microarrays covering approximately 8000 unique genes. The transcriptional programs, including previously published responses to interleukin-3 (IL-3) deprivation and staurosporine treatment, were compared and intersections between pathways were identified. Genes regulated in at least three pathways were chosen as candidate genes. cDNA was isolated for selected candidate genes (Gateway TM cloning system) and was introduced into FL5.12 cells by retroviral transduction. Cells expressing the candidate genes were identified by co-expression of GFP, that also allowed for isolation of expressing cells via FACS sorting. Cell lines were subsequently tested for altered growth characteristics and kinetics of apoptosis-induction To distinguish between a toxic and an antiproliferative effect of TEAP, lipin 1 and GP49B, we expressed these genes, as well as hemoglobin, from an inducible promoter. Figure 4 summarizes the results of these experiments that revealed a rather strong death-inducing effect of TEAP, lipin 1 and GP49 under IL-3 deprivation conditions. In the presence of IL-3, however, no significant increase in apoptotic DNA degradation or death rate could be observed for these genes.
In summary, using the integrated approach described, we identified two different types of novel cellular regulators: First, genes that, when overexpressed, dominantly interfere with cell proliferation in the presence of mitogenic signals but enhance cell death in the absence of growth factor. Second, a hemoglobin, as an apoptosis-inducing gene that accelerates cell death in the absence of survival factor IL-3 but has only weak effects in its presence.
Discussion
Genome-scale expression profiling has matured to a reliable technology used in many laboratories worldwide. The functional interpretation of transcriptional events discovered by DNA microarray technologies however, still presents a major challenge. Combining the power of DNA microarrays with high-throughput methodologies for the assignment of protein function will become ever more important given the plethora of genomic data. From our experience with recombination-based cloning, retroviral transductions of candidate genes and FACS-based phenotypic testing of a set of nine genes, it appears well possible to scale up these experiments to much higher throughput.
We reasoned that cellular responses to stimuli that ultimately lead to similar phenotypic outcomes, might be more likely to share critical parts of the respective pathways than to share 'bystander' effects. Although the anti-cancer drugs that were compared in this study have diverse initial molecular targets, it appeared reasonable to assume that the inhibition of different molecules that are all essential for the progression of the mitotic cycle would often culminate in similar effects on the central cell cycle machinery. We found the largest overlap between transcriptional responses to camptothecin and methotrexate. Our dataset thus provides evidence for common downstream effects of topoisomerase I inhibition by camptothecin and a block of folate dependent enzymes by methotrexate. Shared apoptotic signaling was also suggested by work on human breast cancer cells, showing that insulin-like growth factor 1 (IGF1) suppresses apoptosis upon both, camptothecin and methotrexate treatment (Dunn et al., 1997) . Intersections between the responses to cisplatin treatment on the one side and methotrexate or camptothecin treatment on the other side were of about equal sizes. Presumably, the similarities between these transcriptional programs is due to the fact that camptothecin, methotrexate and also cisplatin all interfere with DNA metabolism rather directly. This is in contrast to the action of paclitaxel that perturbs microtubular dynamics and also caused only a few transcriptional responses overlapping with those of any other treatment.
Our results suggested that intersections of transcriptional pathways may indeed be enriched for regulators with a strong effect on the phenotype as almost 50% of our candidates influenced proliferation or apoptosis when ectopically expressed. Genes that were analysed during this work had not previously been described in the context of B-cell apoptosis and thus represented potential novel regulators. All four candidate genes that had a measurable effect on proliferation or cell death when overexpressed belonged to the group of genes that were upregulated in several apoptotic pathways. The conclusion that only upregulated genes were relevant for cell cycle arrest or the induction of apoptosis would however be premature. Experimental reduction of transcript numbers would rather be required to exhaustively test the contribution of gene repression events to the control of proliferation and cell death. Our observation that pro-apoptotic BAD and pro-apoptotic BAK were both repressed upon prolonged camptothecin treatment reflects that the involvement and function of apoptotic regulators in any specific cell death pathway is not easily predictable but rather needs to be addressed for each pathway individually. Also, it should be kept in mind, that posttranslational modification may counteract the direction of transcriptional regulation, further extending the cell's capacities to fine-tune and integrate multiple signals. These considerations demonstrate the necessity of additional experimental work following initial microarray-based screening for relevant genes. Our finding of an antiproliferative and also toxic effect of GP49B was in good agreement with previous work, showing the inhibitory action of this Ig superfamily- (Wang et al., 2000) . Our results suggest the existence of a receptor-mediated inhibitory pathway in pro B-cells that counteracts the IL-3 mitogenic signal.
Lipin1 was recently identified as a nuclear protein, highly expressed in murine adipose tissue (Peterfy et al., 2001) . Mutations in the Lipin1 gene are causing lipodystrophy in mice but no link to cellular proliferation or apoptosis has been described to date. Our findings point to a regulatory function of lipin1 that is not restricted to adipocytes.
For TEAP, the thymus expressed acidic protein, our data provide evidence for a role in the control of B-cell proliferation and cell death. Remarkably, TEAP was induced in all apoptotic pathways we investigated, pointing to a central role, conserved between drug responses and the physiological reactions to growth factor removal. While writing this manuscript was in progress, Tomasini et al. (2001) identified a nuclear protein, SIP27, and described it as being identical to TEAP. Consistent with our findings, SIP27 and an alternative splice form, SIP18, were both induced in response to various stress conditions like UV irradiation, base damaging, ethanol treatment, heat shock and oxidative stress. Remarkably, SIP27 was able to induce apoptosis also in Cos7 cells when transiently expressed.
Hemoglobin is probably one of the best-characterized proteins with central functions in oxygen transport. Data presented here, however indicate that hemoglobin alpha has an additional function in apoptosis. Our findings show that upregulation of hemoglobin in the absence of IL-3 contributes significantly to caspase activation, chromosomal DNA degradation and subsequent cell death. Suppression of this pro-apoptotic effect by Bcl-2 suggests that hemoglobin acts upstream of Bcl-2 and cannot override Bcl-2 activity. A possible link to apoptotic signaling might be given by the notion that hemoglobin counteracts the anti-apoptotic effect of heme oxygenase by inactivating carbon monoxide, a product of heme oxygenase (Brouard et al., 2000) although the relevance of this finding for the B-cell lineage remains to be determined. Additional evidence for a pro-apoptotic role of hemoglobin comes from the observation that oxyhemoglobin induces caspase-mediated cell death in cerebral endothelial cells (Meguro et al., 2001) . In this cellular background, caspase-8 and caspase-9 are activated by oxyhemoglobin and caspase inhibition is sufficient to block oxyhemoglobin-induced cell death.
The surprising identification of a novel role for hemoglobin also reflects the growing perception that connections between pathways are multifaceted and that there are more than only a few classical pathways of apoptosis (Leist and Ja¨a¨ttela¨, 2001 ).
Materials and methods
Cell lines, cell culture conditions, viability and apoptosis assays Murine FL5.12 neo, FL5.12 Bcl-2 and FL5.12 Bax (CL 16) cells were obtained from Dr S Korsmeyer and had been stably transfected with a vector for G418 resistance. The growth medium was RPMI-1640 supplemented with 10% fetal calf serum and 1 ng/ml of recombinant IL-3 (Sigma).
Cells were grown in a humified atmosphere of 5% CO 2 in the presence of 200 mg/l of G418. For drug treatment experiment cells were grown to a density of 2 -5610 5 cells/ ml before they were subjected to camptothecin (20 mM in DMSO), cisplatin (5 mg/ml in H 2 O), paclitaxel (3 mg/ml in DMSO), or methotrexate (3 mg/ml in DMSO). Concentrations of drugs were chosen such that after 20 h of treatment 10 -30% of cells were dead. At various time points during the drug treatment, cell aliquots were removed, pelleted and stored at 7708C prior to RNA preparation. Cell viability was determined either by trypan blue exclusion or propidium iodide (4 mg/ml, 10 4 -10 5 cells) exclusion with subsequent FACS analysis.
For in-vitro caspase assays, the caspase fluorogenic substrate Ac-Asp-Glu-Val-Asp-AMC (Ac-DEVD-AMC; Bachem AG, Bubendorf, Switzerland) was added to the cell lysate at a final concentration of 20 mM. Buffer concentrations were 18 mM HEPES, 0.9 mM EDTA, 4.5 mM DTT, 0.09% chaps, 9% sucrose. For measurements of caspase activity in the presence of inhibitor, Ac-Asp-Glu-Val-Asp-CHO (Ac-DEVD-CHO) was added to a final concentration of 1 mM and samples were pre-incubated at room temperature with inhibitor prior to the addition of caspase substrate for 30 min. Addition of substrate was followed by incubation at 378C for 2 h. Samples were analysed in duplicate by fluorescence measurement at 390/460 nm. For detection of phosphatidylserine exposure at the cell surface, annexin-V-PE (Becton Dickinson) staining assays were performed. Cells were washed twice in cold PBS and then resuspended in 16 binding buffer (10 mM HEPES, pH 7.4, 140 mM NaCl, 2.5 mM CaCl 2 ) at a concentration of 1610 6 cells/ml. One hundred ml of this suspension were mixed with 5 ml of Annexin V-PE and 5 ml of 7-AAD solution. 7-AAD served as a marker for membrane leakage to distinguish between early apoptotic and dead cells. Samples were subsequently incubated for 15 min at room temperature in the dark. Prior to FACS analysis, the suspension was diluted with 400 ml of 16 binding buffer.
RNA preparation and cDNA microarrays
Total RNA and Poly A + RNA were extracted using RNeasy (Qiagen) followed by Oligotex (Qiagen). RNA quality control was done by reverse transcription PCR using oligonucleotide primers generating intron-spanning amplification products to verify the absence of genomic DNA and mRNA integrity. Production of mouse GEM TM 1 microarrays, probe labeling, hybridization, microarray scanning, normalization and ratio determination were performed by Incyte Pharmaceuticals according to the protocols available from Incyte. Briefly, sequences for arraying are generated by PCR and PCR products are purified by gel filtration and equilibrated in 0.26 SSC. The filtrate is dried down and rehydrated in onetenth-volume dH 2 O for arraying on modified glass slides. Slides are UV crosslinked, washed in dH 2 O and treated with 0.2% I-Block (Tropix, Bedford, MA, USA). Arrays are then rinsed in 0.2% SDS followed by washes in dH 2 O. Fluorescent labeling of probe: Isolated mRNA is reverse transcribed with 5' Cy3 or Cy5 labeled random 9-mers (Operon Technologies, Inc., Alameda, CA, USA). Reactions are incubated for 2 h at 378C with 200 ng polyA + RNA, 200 units M-MLV reverse transcriptase (Life Technologies), 4 mM DTT, 1 unit RNase Inhibitor (Ambion, Austin, TX, USA), 0.5 mM dNTPs, and 2 mg labeled 9-mers in 25 ml volume with enzyme buffer supplied by the manufacturer. The reaction is terminated by incubation at 858C for 5 min. The paired reactions are combined and purified with a TE-30 column (Clonetech, Palo Alto, CA, USA), brought to 90 ml with dH 2 O, and precipitated with 2 ml 1 mg/ml glycogen, 60 ml 5 M NH 4 OAc, and 300 ml EtOH. After centrifugation the supernatant is decanted and the pellet is resuspended in 24 ml of hybridization buffer: 56 SSC, 0.2% SDS, 1 mM DTT. Hybridization: Probe solutions are thoroughly resuspended by incubating at 658C for 5 min with mixing. Eighteen ml of probe is applied to the array, covered with a 2 mm 2 glass coverslip, and placed in a chamber to prevent evaporation. After hybridization at 608C for 6.5 h slides are washed for 10 min in 16 SSC, 0.1% SDS, 1 mM DTT at 458C, 3 min in 0.16 SSC, 0.1% SDS, 1 mM DTT at 208C, and 1 min in reagent alcohol then dried. Scanning: Microarrays were scanned in both Cy3 and Cy5 channels with Axon GenePix TM scanners (Foster City, CA, USA) with a 10 mm resolution. The signal is converted into 16-bits-per-pixel resolution, yielding a 65 536 count dynamic range. Normalization and ratio determination: Incyte GEMTools TM software (Incyte Pharmaceuticals) was used for image analysis. The area surrounding each element image is used to calculate a local background that is subtracted from the total element signal. The average of the resulting total Cy3 and Cy5 signal gives a ratio that is used to balance or normalize the signals.
For investigation of drug responses the sample derived from cells that were grown in the absence of drugs was labeled with CY5 and hybridized to the same chip as the CY3-labeled sample from drug treated cells of the same time point.
Expression data were stored and analysed using the software package CoBi 2.0/Expressionist 2.0 (Gene Data). To derive reliable data from the original data sets we chose very stringent selection criteria in the Expressionist TM software and considered only fluorescence signals as valid if they were at least threefold above the local fluorescence background and covered at least 40% of the individual spotting area.
Cloning of cDNAs, retroviral transfections and FACS sorting
Poly-A + RNA of FL5.12 cells was used as template for cDNA synthesis of candidate genes. The first strand reaction was performed with Superscript TM II (Life Technologies) reverse transcriptase. For second strand synthesis Taq DNA polymerase (Roche Molecular Biochemicals) was utilized. Oligonucleotide primers contained attB sites at their respective 5' ends to render cDNA clones compatible with the GATEWAY TM (Life Technologies) cloning system: Primers 5'-GGGGACAAGTTTGTACAAAAAAGCAGGCTCCatggtgctctctggggaagac-3' and 5'-GGGGACCACTTTGTACAAGAAAGCTGGGTACTAacggtacttggaggtcagcac-3' were used to amplify the hemoglobin gene; 5'-GGGGACAAGTTTGTACAAAAAAGCAGGCTCCatgtctcagagcaaccgggagctgg-3' and GGGGACCACTTTGTACAAGAAAGCTGGGTActatttccgactgaagagtgagcccagcag-3' for Bcl-XL; 5'-GGGGACAAGTTTGTACAAAAAAGCAGGCTCCatgtttcagagactgaataaaatgtttg-3' and 5'-GGGGACCACTTTGTAC-In a first cloning step, PCR products were introduced into the pDONR TM (Life Technologies) vector via the BP TM reaction and verified by sequencing. Subsequently cDNA inserts were transferred to retrovirus-derived, GATEWAY TM compatible expression vectors via the LR clonase TM reaction. Once constructs had been verified by restriction digestion, they were transfected using the calcium-phosphate method into a 293T-derived Phoenix packaging cell line expressing an ecotropic envelope protein. Virus containing supernatant of Phoenix cells was then used to transduce FL5.12neo or FL5.12-Bcl2 cells (Swift et al., 1999) . The efficiency of transduction and the level of expression were followed by monitoring the fluorescence intensity of co-expressed GFP in a FACS Calibur instrument (Becton Dickinson). Depending on the viability of isolated expressing cells, 1 -3 rounds of FACS sorting were performed to enrich for cells with maximum expression levels.
Alternatively, we combined the Tet-Off gene expression system of Clontech with our Gateway TM -compatible retroviral constructs to allow for inducible expression of antiproliferative and toxic genes. Expression of candidate genes was therefore performed in a FL5.12tTA cell line, stably expressing the tetracyclin-controlled transactivator (tTA) fusion protein that is composed of the Tet repressor and the VP16 activation domain. Candidate genes were repressed in the presence of 10 ng/ml doxycyclin and were induced upon removal of doxycyclin for 24 h. Sorting of GFP positive cells was performed after transient induction of gene expression.
